Head to Head Review: Longevity Health (NASDAQ:XAGE) & Profusa (NASDAQ:PFSA)

Profusa (NASDAQ:PFSA) and Longevity Health (NASDAQ:XAGE) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Insider & Institutional Ownership

9.8% of Profusa shares are owned by institutional investors. Comparatively, 24.2% of Longevity Health shares are owned by institutional investors. 11.4% of Profusa shares are owned by company insiders. Comparatively, 29.0% of Longevity Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Profusa and Longevity Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Longevity Health	0	0	0	0	0.00

Profitability

This table compares Profusa and Longevity Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Longevity Health	-682.67%	N/A	-261.90%

Volatility and Risk

Profusa has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500. Comparatively, Longevity Health has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Valuation and Earnings

This table compares Profusa and Longevity Health”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$8.71 million	($2.23)	-0.05
Longevity Health	$1.05 million	0.64	-$10.37 million	($3.91)	-0.10

Profusa has higher earnings, but lower revenue than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Summary

Longevity Health beats Profusa on 5 of the 9 factors compared between the two stocks.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.